{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Day 7"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Day 14"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"Day 21"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}],"title":"Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}],"title":"Day 56"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"title":"Day 80"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"}]}],"title":"1 year"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"}]}],"title":"2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Count of participants who experienced dominance of one cord blood unit (defined by \\>or= 95% contribution of one cord blood unit to BM and all PB fractions -- CD3+, CD33+, CD56+, and CD19+) at 7 days, 14 days, 21 days, 28 days, 56 days, and 80 days, 6 months, 1 and 2 years post transplant.","groups":[{"description":"Subjects with hematological malignancies with prior autologous transplant, \\>2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months, OR subjects with refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy.\n\n* Cyclophosphamide 50 mg/Kg Day -6\n* Fludarabine 40mg/m2 Days -6 to -2\n* TBI 200 cGy Day -1\n\nImmune suppression: begin Day -3 cyclosporine and mycophenolate mofetil","id":"OG000","title":"Cyclophosphamide/Fludarabine/TBI"},{"description":"Subjects with hematological malignancies with prior autologous transplant \\>12 mos or \\<1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months.\n\n* Cyclophosphamide 50 mg/Kg Day -6\n* Fludarabine 40mg/m2 Days -6 to -2\n* TBI 200 cGy Day -1\n* Equine ATG 30mg/Kg Days -6 to -4\n\nImmune suppression: begin Day -3 cyclosporine and mycophenolate mofetil","id":"OG001","title":"Cyclophosphamide/Fludarabine/TBI/ATG"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"7 days, 14 days, 21 days, 28 days, 56 days, and 80 days, 6 months, 1 and 2 years post transplant","title":"Chimerism","type":"SECONDARY","unitOfMeasure":"Participants"}